These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses. Mohanty IR, Borde M, Kumar C S, Maheshwari U. Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318 [Abstract] [Full Text] [Related]
34. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. Kushwaha RN, Haq W, Katti SB. Curr Med Chem; 2014 Apr; 21(35):4013-45. PubMed ID: 25245373 [Abstract] [Full Text] [Related]
37. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. Lin K, Cai Z, Wang F, Zhang W, Zhou W. Chem Pharm Bull (Tokyo); 2013 Apr; 61(4):477-82. PubMed ID: 23358258 [Abstract] [Full Text] [Related]
38. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution. Musoev A, Numonov S, You Z, Gao H. Molecules; 2019 Aug 07; 24(16):. PubMed ID: 31394858 [Abstract] [Full Text] [Related]
39. Discovery of anthraquinones as DPP-IV inhibitors: Structure-activity relationships and inhibitory mechanism. Ma HH, Zhang J, Li CQ, Zou LW. Fitoterapia; 2023 Jul 07; 168():105549. PubMed ID: 37244503 [Abstract] [Full Text] [Related]